The FDA granted fast track designation for CTx001, an investigational gene therapy candidate for geographic atrophy secondary to age-related macular degeneration.
According to a press release from Complement Therapeutics, CTx001, an adeno-associated virus-based therapy, is designed to treat GA by delivering a truncated version of complement receptor 1, with the aim of yielding “long-term potent modulation of the classical and alternative pathways of the complement cascade.”
The FDA grants fast track designation to expedite the development and review of therapies that treat serious conditions